^
Association details:
| Biomarker: | STK11 mutation + KEAP1 mutation + KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.
Published date:
05/25/2023
Excerpt:
105 pts with advanced KRAS G12C-mutant NSCLC treated with sotorasib were identified….Dual STK11/KEAP1 co-mutation status was associated with shorter OS compared to STK11 wild-type (WT)/KEAP1 mutant (MUT) status (OS HR 4.04, P = 0.033) and STK11 MUT/KEAP1 WT status (OS HR 5.41, P = 0.012).
DOI:
10.1200/JCO.2023.41.16_suppl.9083
